Annual trends in adverse events following mumps vaccination in Japan: A retrospective study

Vaccine. 2022 Feb 11;40(7):988-993. doi: 10.1016/j.vaccine.2022.01.008. Epub 2022 Jan 17.

Abstract

Background: In Japan, a monovalent mumps vaccine is provided on a voluntary basis. Due to public concerns over post-vaccination aseptic meningitis, the vaccination coverage is not high enough. The present study investigated the incidence of adverse events, including aseptic meningitis, after Torii strain-derived mumps vaccination.

Methods: This retrospective, observational study used data collected by a vaccine manufacturer regarding adverse events following mumps vaccinations at medical institutions between 1992 and 2018. In addition, the number of Torii strain-derived mumps vaccines shipped each year was obtained. The incidence (per 100,000 doses) and 95% confidence intervals (CIs) were calculated for all adverse events and each adverse event, categorized as aseptic meningitis, encephalitis, mumps, mumps complications, and others.

Results: During the study period, 8,262,121 mumps vaccine doses were shipped, and 688 subjects reported adverse events. The incidence for all adverse events (per 100,000 doses) was 8.33, and the incidence was 4.19 for aseptic meningitis, 0.33 for encephalitis, 0.80 for mumps, 0.25 for mumps complications, and 3.78 for others. The incidence of aseptic meningitis (per 100,000 doses) was 7.90 (95% CI: 5.61-10.18) between 1998 and 2000 but declined by half, to 3.91 (2.46-5.36), between 2001 and 2003. The most recent incidence (per 100,000 doses) of aseptic meningitis, for the period 2016 to 2018, was 2.78 (1.94-3.62).

Conclusion: The incidence of post-vaccination aseptic meningitis has declined significantly since 2001, and the incidence has remained stable at fewer than 3 cases per 100,000 doses since 2010. Multiple factors might have contributed to the decline in aseptic meningitis incidence, including (i) lowered misclassification of aseptic meningitis resulting from echovirus infection; (ii) changes in the vaccine manufacturing process in 2000; and (iii) publication in 2008 of the recommendation for vaccination of children at 1 year of age.

Keywords: Adverse events; Aseptic meningitis; Database; Incidence; Mumps vaccine.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Humans
  • Infant
  • Japan / epidemiology
  • Measles-Mumps-Rubella Vaccine
  • Meningitis, Aseptic* / epidemiology
  • Meningitis, Aseptic* / etiology
  • Mumps Vaccine / adverse effects
  • Mumps* / complications
  • Mumps* / epidemiology
  • Mumps* / prevention & control
  • Retrospective Studies
  • Vaccination / adverse effects

Substances

  • Measles-Mumps-Rubella Vaccine
  • Mumps Vaccine